
InfuSystem Hlds (INFU) Stock Forecast & Price Target
InfuSystem Hlds (INFU) Analyst Ratings
Bulls say
InfuSystems Holdings Inc. has demonstrated strong financial performance, with core oncology business achieving record quarterly revenue and a significant new contract with a major hospital system expected to enhance patient volumes in the upcoming quarter. The gross profit margin improved by 370 basis points to 55.2%, driven by strategic revenue mix optimization and normalized pump disposal costs, which supports sustainable profitability. Additionally, the year-to-date net operating cash flow reached $17.3 million, reflecting a 38% increase attributed to enhanced earnings and effective working capital management, positioning the company for future growth as auxiliary services in Wound Care and Pain Management gain traction.
Bears say
InfuSystems Holdings Inc has encountered a deterioration in gross margins, predominantly due to challenges within its lower-margin Device Solutions division, alongside increasing operational costs. Economic uncertainties have exacerbated the situation by prompting customer destocking, leading to diminished demand and reduced sales volumes, which have further exerted downward pressure on margins. The projected revenue for Fiscal Year 2026 reflects a stagnant forecast of $143.6 million, marking a decrease of $9.5 million compared to prior estimates, as various factors such as competitive headwinds and margin compression pose significant risks to the company's financial performance.
This aggregate rating is based on analysts' research of InfuSystem Hlds and is not a guaranteed prediction by Public.com or investment advice.
InfuSystem Hlds (INFU) Analyst Forecast & Price Prediction
Start investing in InfuSystem Hlds (INFU)
Order type
Buy in
Order amount
Est. shares
0 shares